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856 Abstracts September 2013Methods: Systematic extraction of MAs and SRs, published in the
Journal of Vascular Surgery between 2010 and 2012, was performed and
included all 27 PRISMA items. For each article, two scores were calculated:
“Points,” where maximally “72” points could be scored per article; and
“Ratio,” where a point fraction could be scored for each PRISMA item.
Results are means 6 standard deviation.
Results: Of 1820 articles totally, 37 were MAs and 18 SRs. From
2010 to 2012, a signiﬁcant decrease in the number of published random-
ized controlled trials and increase in MAs was observed (P ¼ .047),
while SRs remained stable. The average “Points” score for MAs was 45
6 11 and “Ratio” score 17 6 4.7. For SRs, the average “Points”
score was 33 6 11 and “Ratio” score 11 6 3.6. Although statistically
insigniﬁcant, a trend towards improved reporting over time was observed
(P ¼ .271).
Conclusions: As the number of randomized controlled trials in
vascular surgery continues to diminish, the role of SRs and MAs in providing
evidence-based information becomes more important. However, the clarity
and transparency of SRs and MAs are not optimal. Improved conduct and
reporting will be important to advance health care decision-making and
better identify targets for future research.Fig.
Table. Multivariable predictors of ASC complications
Hazard
ratio
95% Conﬁdence
interval P value
Age – – –
<65 years 1.65 0.81-3.33 .167
65-74 years 2.37 1.27-4.42 .006
Preoperative warfarin use 2.46 1.44-4.19 .001
Vascular closure devices vs
manual compression
0.64 0.37-1.13 .124
Post- vs pre-RUS period 0.50 0.29-0.86 .012
ASC, Access-site-related complications; RUS, routine ultrasound-guided.Factors Associated with Femoral Artery Access Site Hematoma
Following Peripheral Vascular Intervention
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School of Public Health, Boston, MassObjectives: Local vascular complications have a reported incidence of
1% to 7% and are the most frequent adverse outcome of femoral arterial
access. This study aimed to identify variables associated with groin hema-
toma after peripheral vascular intervention (PVI).
Methods: The Vascular Study Group of New England (VSGNE)
database (2010-2012) was queried to identify the complication of postpro-
cedural groin hematoma after 4930 PVIs performed via femoral arterial
access. Hematoma (including pseudoaneurysms) was deﬁned as minor
(requiring compression or observation), moderate (requiring transfusion
or thrombin injection), and major (requiring operation). Associated vari-
ables were identiﬁed using multivariable logistic regression models.
Results: The overall post-procedural groin hematoma rate after PVI
was 4.7%, and the rate of moderate/major hematoma was 0.9%. Groin
hematoma had no effect on mortality, but was associated with increased
mean hospital length of stay (3.3 days vs 2 days; P < .001). Independent
predictors of hematoma included: age>80 years (odds ratio [OR] 2.16,
95% CI, 1.04-4.52; P ¼ .04), female gender (OR, 1.81; 95% CI, 1.37-
2.40; P < .001), bilateral femoral access (OR, 1.61; 95% CI, 1.16-2.24;
P ¼ .005), and sheath size >6 French (OR, 1.61; 95% CI, 1.18-2.22;
P ¼ .003). Use of closure devices was protective against hematoma (OR,
0.48; 95% CI, 0.35-0.66; P < .001), as was performance of PVI in the
second half of the academic year (January through June; OR, 0.71; 95%
CI, 0.54-0.93; P < .02). Neither ultrasound guidance nor body mass index
had any effect on hematoma rates.
Conclusions: Many important risk factors that predict hematoma
formation after femoral arterial access for PVI are not modiﬁable. However,
the appropriate use of smaller sheaths as well as closure devices may poten-
tially protect against the complication of hematoma, and may provide
a quality improvement opportunity to decrease patient morbidity as well
as hospital resource utilization.Predictors of Access-Site-Related Complications After Lower Extremity
Percutaneous Revascularization
Ruby C. Lo, Margriet T.M. Fokkema, Thomas Curran, Raul J. Guzman,
Allen D. Hamdan, Mark Wyers, Elliot L. Chaikof, Marc L.
Schermerhorn. Beth Israel Deaconess Medical Center, Boston, Mass
Objectives: Though well described in the cardiology literature, less is
known about risks for access-site-related complications (ASC) following
percutaneous lower extremity revascularization. We also sought to eval-
uate the beneﬁt of routine ultrasound-guided access (RUS) in decreasing
ASC.
Methods: We reviewed all percutaneous revascularizations (percuta-
neous transluminal. angioplasty or stent) performed for lower extremity
atherosclerosis at our institution from 2002 to 2012. RUS began in October
2007. Primary outcome was any ASC (bleeding, groin or retroperitoneal
[RP] hematoma, vessel rupture, or thrombosis). Multivariable logistic
regression was used to determine predictors of ASC.
Results: A total of 1419 punctures were performed on 925 patients
(43% women; median age, 69 years [interquartile range, 60-78 years])
for claudication (30%), critical limb ischemia (58%), or other (12%) using
4- to 8-Fr sheaths. Seventy-six ASC occurred (5.4%): 15 instances of
bleeding, 41 groin and eight RP hematoma, two artery ruptures, nine
pseudoaneurysms, and one thrombosis. Computed tomography evalua-
tion was done in 13, thrombin injection in nine, and operative repair
in 20 patients. ASC were more common before RUS (7.6% vs 4.5%; P
¼ .026). Multivariable predictors of ASC were older age, preoperative
warfarin use, and procedure performance before RUS (Table). Vascular
closure devices were not associated with ASC rates but when
attempted, failures were associated with a higher ASC rate (15% vs 4%;
P ¼ .006).
Conclusions: RUS has decreased ASC in recent years but vascular
closure devices have not demonstrated a signiﬁcant impact. Particular care
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preoperatively.Fate of Type I Endoleaks Following EVAR
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Objectives: This study evaluated the incidence and outcomes of
secondary procedures for Type I endoleaks following endovascular aneu-
rysm repair (EVAR).
Methods: From 2002 to 2013, 2496 patients underwent EVAR for
treatment of nonruptured (n ¼ 2315; 93%) and ruptured (n ¼ 181; 7%)
abdominal aortic aneurysms (AAAs). Postoperative follow-up included clin-
ical examination, ultrasound, and computed tomography at 1, 6, and 12
months, and yearly thereafter. Patients with Type I endoleaks were either
observed without any intervention, underwent endovascular interventions,
or surgical explant. Data was prospectively collected.
Results: Of 2496 patients that underwent EVAR, over a mean follow-
up of 57 months, 202 (8%) patients were discovered to have Type I endo-
leaks from proximal (n ¼ 111; 55%), distal (n ¼ 69; 34%), or proximal and
distal (n ¼ 22; 11%) stent graft ﬁxation sites. The mean age was 74 years,
and the maximum AAA diameter was 6.0 cm. Indications for treatment
included asymptomatic Type I endoleaks (n ¼ 171; 85%), symptomatic
aneurysms (n ¼ 14; 7%), or aneurysm rupture (n ¼ 17; 8%). In 49 (24%)
patients, Type I endoleaks resolved without any further intervention. Treat-
ments included embolization procedures only in 17 (8%), stent graft exten-
sions only in 103 (51%), embolization and stent graft extensions in 19 (9%),
and stent graft explant in 14 (7%). Multiple endovascular procedures were
required in 41 (20%) patients. Overall operative mortality for all Type I
endoleaks was 1.5%; all deaths occurred in patients that presented with
ruptured AAAs (3/17; 18%).
Conclusions: Our single center long-term EVAR experience indicates
that 8% of patients developType I endoleaks. The vastmajority of Type I endo-
leaks can be treated by endovascular means with limited mortality, and embo-
lization procedures alone can be effective in select patients. If untreated, 24%
of Type I endoleaks resolve spontaneously, while 26% lead to AAA rupture.Prospective Multicenter International Trial of EndoAnchor Fixation
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Results in the ANCHOR Trial
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Objectives: Endograft ﬁxation and sealing are important determi-
nants of durability after endovascular abdominal aortic aneurysm repair
(EVAR). This study was undertaken to assess the safety and efﬁcacy of
EndoAnchors to augment proximal ﬁxation and sealing in a globally-
setting.
Methods: The 149 subjects have been enrolled at 23 U.S. and four
European centers over 15 months through mid-April, 2013. EndoAnchors
implanted prophylactically at initial EVAR (“PRIMARIES,” N ¼ 111; 74%)
or therapeutically for existing type Ia endoleak/migration after the index
EVAR procedure (“REVISIONS,” N ¼ 38; 26%). The primary endpoint
was successful EndoAnchor deployment without type Ia endoleak/migra-
tion over time. A conical neck was deﬁned by diameter increase >10%
over 10 mm length.
Results: The endografts used were Endurant (57; 51%), Excluder
(30; 27%), and Zenith (24; 22%) in PRIMARIES, and Excluder (7; 18%),
AneuRx (10; 26%), Talent (6; 16%), Zenith (5; 13%), Endurant (5; 13%),
and other (5; 13%) in REVISIONS. Proximal necks averaged 18.6 6
11.2 mm in length (28% #10 mm), 25.1 6 4.5 mm in diameter, with 33
6 22 degrees of angulation; 41% were conical. An average of 5.3 EndoAn-
chors were implanted in PRIMARIES and 6.2 in REVISIONS. The most
common indication for EndoAnchor use was a hostile neck in PRIMARIES
(88%) and existing type Ia endoleak in REVISIONS (76%). Procedural
success was conﬁrmed in 99% (109/110) of the PRIMARIES and 92%
(35/38) in REVISIONS. Type Ia endoleaks were absent at 1-month in
96/99 (97%) of PRIMARIES and 32/36 (89%) of REVISIONS.
Conclusions: EndoAnchor use was associated with satisfactory early
results when high-risk anatomy was encountered at an initial EVAR proce-
dure and was successful in repairing most proximal neck problems in EVAR
revisions. Long-term data will be collected to assess the effectiveness of
EndoAnchors in preventing late complications.
